Knee Osteoarthritis Pipeline Analysis 2025: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Knee Osteoarthritis Pipeline

“Knee Osteoarthritis Pipeline Insight, 2025″report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Knee Osteoarthritis Market. The Knee Osteoarthritis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Knee Osteoarthritis Clinical Trials Assessment

Some of the key takeaways from the Knee Osteoarthritis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Knee Osteoarthritis treatment therapies with a considerable amount of success over the years.
• Knee Osteoarthritis companies working in the treatment market are Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia and others, are developing therapies for the Knee Osteoarthritis treatment
• Emerging Knee Osteoarthritis therapies such as Lorecivivint, LG00034053, EP-104IAR, Clodronate, SYN321, AMZ001 Diclofenac gel, Allocetra, ANT-301, Mesenchymal Stem Cells, JointStem, LY3016859 ISA, Retatrutide, LEVI-04, TD0015, Vutiglabridin, Artrodar, OA-SYS, Celecoxib + Acetaminohen, SP5M002 inj, Cannabidiol, SAR446959, TPX-100, KBP-336 and others are expected to have a significant impact on the Knee Osteoarthritis market in the coming years.
• In September 2025, Synartro AB announced results of a Prospective, Double-blinded, Randomized, Placebo-controlled Phase 1/2a Study to Assess Safety, Tolerability, Systemic Exposure, and Preliminary Efficacy of Single Intraarticular Injections of 3 Dose Levels of SYN321 and Placebo in Patients With Symptomatic Knee Osteoarthritis.
• In August 2025, Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive three-month topline data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II double-blind, randomized, placebo-controlled clinical trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.
• In August 2025, Enlivex Therapeutics Ltd announced results of a Phase 1/2a Randomized, Double-Blind Placebo-controlled Study of Intra-articular Allocetra in Knee Osteoarthritis
• In May 2025, Lipogems announced the successful completion of its ARISE I U.S. FDA IDE Study, with the final patient visit now concluded. This marks a significant milestone in progressing Lipogems as a treatment option for knee osteoarthritis (OA) in patients who are not eligible for or ready to undergo knee replacement. The double-blind, randomized controlled trial included 173 participants across 18 leading U.S. clinical sites. The study’s primary focus is on assessing pain relief and functional improvement 12 months after injection. Results on efficacy and safety are anticipated by late 2025.
• In May 2025, Genascence Corporation, a clinical-stage biotech firm focused on transforming musculoskeletal disease treatment through gene therapy, reported positive 12-month safety and biomarker findings from its Phase 1b DONATELLO trial of GNSC-001. This investigational gene therapy targets interleukin 1 (IL-1) for treating knee osteoarthritis (OA). The 12-month results confirmed the trial met its primary endpoint, showing consistent safety and tolerability across all tested doses. Additionally, the study met a key secondary endpoint, demonstrating sustained IL-1Ra expression in synovial fluid, reinforcing the six-month data previously reported.
• In May 2025, Moximed, a pioneering medical device company focused on enhancing care for individuals with knee osteoarthritis (OA), announced that the first patients have been treated in its latest randomized controlled trial (RCT). The MOTION study is a prospective, multicenter trial designed to compare the effectiveness of the MISHA Knee System against non-surgical treatment options in patients with medial knee osteoarthritis.
• In April 2025, Pacira BioSciences reported that its gene therapy candidate, PCRX-201 (enekinragene inzadenovec), showed long-lasting improvements in knee pain, mobility, and stiffness for up to two years in a Phase I trial. Participants received a single local injection of the therapy. The study included 72 individuals aged 30 to 80, categorized based on the severity of their knee osteoarthritis using the Kellgren-Lawrence (K/L) grading system.
• In April 2025, Israel-based Enlivex Therapeutics announced the completion of enrollment for the Phase II portion of its Phase I/II trial evaluating Allocetra, an off-the-shelf cell therapy for moderate to severe knee osteoarthritis. In this phase, over 133 subjects were randomized and treated. The multi-center, randomized trial is divided into two stages, with Phase I being an open-label, dose-escalation study focused on assessing the safety and tolerability of Allocetra injections into the knee.
• In March 2025, RION, a clinical-stage company specializing in regenerative medicine and exosome-based therapies, announced the enrollment of the first patient in its Phase 1b trial of Purified Exosome Product™ (PEP™) for treating Knee Osteoarthritis (OA). This marks a significant step in RION’s mission to develop cutting-edge regenerative solutions for unmet medical needs.

Knee Osteoarthritis Overview

Knee Osteoarthritis (OA) is a progressive degenerative joint disorder characterized by cartilage breakdown, synovial inflammation, and changes in subchondral bone, leading to chronic pain, stiffness, and reduced mobility. It is the most common form of arthritis, affecting millions worldwide, particularly older adults. Risk factors include age, obesity, joint injury, genetics, and mechanical stress. Current treatments focus on symptom management with analgesics, corticosteroids, physical therapy, and lifestyle modifications, but no approved therapies halt disease progression. Novel approaches, including disease-modifying drugs, regenerative therapies, and long-acting injectables, are under development to address the unmet need for effective, sustained treatment options in knee Osteoarthritis.

Get a Free Sample PDF Report to know more about Knee Osteoarthritis Pipeline Therapeutic Assessment- Knee Osteoarthritis Drugs and Therapies

Knee Osteoarthritis Emerging Drugs Analysis

Lorecivivint – Biosplice Therapeutics

Lorecivivint (SM04690) is a small-molecule CLK/DYRK1A inhibitor that modulates Wnt and inflammatory pathways. Preclinical data suggest it reduces inflammation, slows cartilage loss, and promotes cartilage growth. It is currently in Phase III trials for Knee Osteoarthritis.

EP-104IAR – Eupraxia Pharmaceuticals

EP-104IAR is a long-acting corticosteroid (fluticasone propionate) injection using Eupraxia’s polymer-based delivery system. Designed for Knee OA, it provides pain relief for up to six months with fewer side effects compared to existing corticosteroids. It is in Phase II development.

LG00034053 – LG Chem

LG00034053 is an injectable drug targeting inflammatory pathways and preventing chondrocyte apoptosis. Early studies show long-lasting pain relief and protection against cartilage damage. It is in Phase I/II clinical development for Knee Osteoarthritis.

Knee Osteoarthritis Route of Administration

Knee Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Knee Osteoarthritis Molecule Type

Knee Osteoarthritis Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Knee Osteoarthritis Pipeline Therapeutics Assessment

• Knee Osteoarthritis Assessment by Product Type
• Knee Osteoarthritis By Stage and Product Type
• Knee Osteoarthritis Assessment by Route of Administration
• Knee Osteoarthritis By Stage and Route of Administration
• Knee Osteoarthritis Assessment by Molecule Type
• Knee Osteoarthritis by Stage and Molecule Type

DelveInsight’s Knee Osteoarthritis Report covers around 60+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Knee Osteoarthritis product details are provided in the report. Download the Knee Osteoarthritis pipeline report to learn more about the emerging Knee Osteoarthritis therapies- Knee Osteoarthritis Medication and FDA Approvals

Knee Osteoarthritis Pipeline Analysis:

The Knee Osteoarthritis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Knee Osteoarthritis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Knee Osteoarthritis Treatment.
• Knee Osteoarthritis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Knee Osteoarthritis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Knee Osteoarthritis market.

Download Sample PDF Report to know more about Knee Osteoarthritis drugs and therapies- Knee Osteoarthritis Competitive Landscape

Scope of Knee Osteoarthritis Pipeline Drug Insight

• Coverage: Global
• Key Knee Osteoarthritis Companies: Bone Therapeutics, Moebius Medical, UnicoCell Biomed CO. LTD, Gwo Xi Stem Cell Applied Technology, Bioventus LLC, CAR-T (Shanghai) Biotechnology, Novartis, Personalized Stem Cells, Centrexion Therapeutics, Akan Biosciences, Samumed LLC, Purdue Pharma, Anika Therapeutics, Peptinov SAS, Flexion Therapeutics, Taiwan Liposome Company, Techfields Pharma, AstraZeneca, Ampio Pharmaceuticals, BioIntegrate, Sorrento Therapeutics, Swiss Medica XXI Century S.A., OrthoTrophix, R-Bio, Amzell, Eupraxia Pharmaceuticals, Meluha Life Sciences SDN BHD, Vivex Biomedical, Orient Europharma Co., Ltd., Paradigm Biopharmaceuticals, Abbvie, Galapagos NV, Regeneron Pharmaceuticals, Xalud Therapeutics, Yooyoung Pharmaceutical, Celltex Therapeutics Corporation, Eli Lilly and Company, Sclnow Biotechnology, Mestex AG, Mitsubishi Tanabe Pharma Corporation, Propella Therapeutics, PT. Prodia Stem Cell Indonesia, and others.
• Key Knee Osteoarthritis Therapies: Lorecivivint, LG00034053, EP-104IAR, Clodronate, SYN321, AMZ001 Diclofenac gel, Allocetra, ANT-301, Mesenchymal Stem Cells, JointStem, LY3016859 ISA, Retatrutide, LEVI-04, TD0015, Vutiglabridin, Artrodar, OA-SYS, Celecoxib + Acetaminohen, SP5M002 inj, Cannabidiol, SAR446959, TPX-100, KBP-336 and others.
• Knee Osteoarthritis Therapeutic Assessment: Knee Osteoarthritis current marketed and Knee Osteoarthritis emerging therapies
• Knee Osteoarthritis Market Dynamics: Knee Osteoarthritis market drivers and Knee Osteoarthritis market barriers

Request for Sample PDF Report for Knee Osteoarthritis Pipeline Assessment and clinical trials – Knee Osteoarthritis Therapeutics Assessment

Table of Contents

1. Knee Osteoarthritis Report Introduction

2. Knee Osteoarthritis Executive Summary

3. Knee Osteoarthritis Overview:

4. Knee Osteoarthritis- Analytical Perspective In-depth Commercial Assessment

5. Knee Osteoarthritis Pipeline Therapeutics

6. Knee Osteoarthritis Late Stage Products (Phase II/III)

7. Knee Osteoarthritis Mid Stage Products (Phase II)

8. Knee Osteoarthritis Early Stage Products (Phase I)

9. Knee Osteoarthritis Preclinical Stage Products

10. Knee Osteoarthritis Therapeutics Assessment

11. Knee Osteoarthritis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Knee Osteoarthritis Companies

14. Knee Osteoarthritis Key Products

15. Knee Osteoarthritis Unmet Needs

16. Knee Osteoarthritis Market Drivers and Barriers

17. Knee Osteoarthritis Future Perspectives and Conclusion

18. Knee Osteoarthritis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services